BL 1827

Drug Profile

BL 1827

Alternative Names: Analgesic sublingual spray - Bioglan Pharma/CeNeS Pharmaceuticals; Opioid sublingual aerosol spray

Latest Information Update: 12 Aug 2002

Price : $50

At a glance

  • Originator Bioglan Pharma [CEASED]
  • Class Analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer pain; Postoperative pain

Most Recent Events

  • 12 Aug 2002 Discontinued - Phase-I for Postoperative pain in United Kingdom (Sublingual)
  • 12 Aug 2002 Discontinued - Phase-I for Cancer pain in United Kingdom (Sublingual)
  • 12 Aug 2002 The agent is available for licensing (www.cenes.uk.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top